Knight Therapeutics Inc
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for p… Read more
Market Cap & Net Worth: Knight Therapeutics Inc (KHTRF)
Knight Therapeutics Inc (PINK:KHTRF) has a market capitalization of $435.88 Million ($435.88 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #13410 globally and #5559 in its home market, demonstrating a 3.73% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Knight Therapeutics Inc's stock price $4.39 by its total outstanding shares 99289228 (99.29 Million).
Knight Therapeutics Inc Market Cap History: 2015 to 2025
Knight Therapeutics Inc's market capitalization history from 2015 to 2025. Data shows change from $543.39 Million to $435.88 Million (-2.71% CAGR).
Knight Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Knight Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.00x
Knight Therapeutics Inc's market cap is 1.00 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
85.95x
Knight Therapeutics Inc's market cap is 85.95 times its annual earnings
10.29x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $543.39 Million | $1.04 Million | $34.17 Million | 524.00x | 15.90x |
| 2016 | $786.57 Million | $5.94 Million | $18.56 Million | 132.42x | 42.38x |
| 2017 | $645.32 Million | $8.63 Million | $17.24 Million | 74.74x | 37.42x |
| 2018 | $566.91 Million | $12.50 Million | $24.08 Million | 45.35x | 23.54x |
| 2019 | $581.83 Million | $47.46 Million | $14.52 Million | 12.26x | 40.08x |
| 2020 | $417.01 Million | $199.52 Million | $31.76 Million | 2.09x | 13.13x |
| 2021 | $413.14 Million | $243.48 Million | $15.68 Million | 1.70x | 26.36x |
| 2022 | $377.30 Million | $293.56 Million | -$29.89 Million | 1.29x | N/A |
| 2023 | $393.19 Million | $328.20 Million | -$16.84 Million | 1.20x | N/A |
| 2024 | $372.33 Million | $371.30 Million | $4.33 Million | 1.00x | 85.95x |
Competitor Companies of KHTRF by Market Capitalization
Companies near Knight Therapeutics Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Knight Therapeutics Inc by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Knight Therapeutics Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Knight Therapeutics Inc's market cap moved from $543.39 Million to $ 435.88 Million, with a yearly change of -2.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $435.88 Million | +17.07% |
| 2024 | $372.33 Million | -5.30% |
| 2023 | $393.19 Million | +4.21% |
| 2022 | $377.30 Million | -8.68% |
| 2021 | $413.14 Million | -0.93% |
| 2020 | $417.01 Million | -28.33% |
| 2019 | $581.83 Million | +2.63% |
| 2018 | $566.91 Million | -12.15% |
| 2017 | $645.32 Million | -17.96% |
| 2016 | $786.57 Million | +44.75% |
| 2015 | $543.39 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Knight Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $435.88 Million USD |
| MoneyControl | $435.88 Million USD |
| MarketWatch | $435.88 Million USD |
| marketcap.company | $435.88 Million USD |
| Reuters | $435.88 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.